Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer.

Arias-Pinilla GA, Dalgleish AG, Mudan S, Bagwan I, Walker AJ, Modjtahedi H.

Sci Rep. 2020 Jan 17;10(1):537. doi: 10.1038/s41598-019-57287-w.

2.

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.

Dalgleish AG, McLean E, Patel N, Rahman N.

Respir Med Case Rep. 2019 Nov 21;29:100971. doi: 10.1016/j.rmcr.2019.100971. eCollection 2020.

3.

Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy?

Dalgleish AG.

Expert Rev Anticancer Ther. 2019 Dec;19(12):1001-1003. doi: 10.1080/14737140.2019.1696676. Epub 2019 Nov 29. No abstract available.

PMID:
31760839
4.

The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy.

Dalgleish AG, Di Palma S, Nathan K, Powell B, Patel N, Fusi A.

Eur J Cancer. 2019 May;113:14-18. doi: 10.1016/j.ejca.2019.03.005. Epub 2019 Apr 4. No abstract available.

PMID:
30954882
5.

In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells.

Gravett AM, Dalgleish AG, Copier J.

Sci Rep. 2019 Feb 7;9(1):1544. doi: 10.1038/s41598-018-38190-2.

6.

The failure of radical treatments to cure cancer: can less deliver more?

Dalgleish AG, Stern PL.

Ther Adv Vaccines Immunother. 2018 Dec 20;6(5-6):69-76. doi: 10.1177/2515135518815393. eCollection 2018 Sep. Review.

7.

Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine.

Leeman H, Kaminska E, Green D, Bodman-Smith M, Gravett A, Bodman-Smith K, Copier J, Coulton G, Fusi A, Dalgleish AG.

Transl Oncol. 2019 Mar;12(3):397-403. doi: 10.1016/j.tranon.2018.11.002. Epub 2018 Dec 8.

9.

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.

Gravett AM, Trautwein N, Stevanović S, Dalgleish AG, Copier J.

Oncoimmunology. 2018 Mar 6;7(6):e1438107. doi: 10.1080/2162402X.2018.1438107. eCollection 2018.

10.

Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.

Arias-Pinilla GA, Dalgleish AG, Mudan S, Bagwan I, Walker AJ, Modjtahedi H.

Oncotarget. 2018 Apr 13;9(28):19994-20007. doi: 10.18632/oncotarget.25017. eCollection 2018 Apr 13.

11.

The Third Institute for Cancer Vaccines and Immunotherapy (ICVI) symposium on immunotherapy: May 12-13, 2017, Royal Society, London, UK.

Dalgleish AG.

Cancer Immunol Immunother. 2018 May;67(5):855-860. doi: 10.1007/s00262-018-2137-9. Epub 2018 Mar 2. No abstract available.

12.

Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors.

Cant R, Dalgleish AG, Allen RL.

Front Immunol. 2017 Jul 11;8:809. doi: 10.3389/fimmu.2017.00809. eCollection 2017.

13.

Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration.

Scott KA, Dalgleish AG, Liu WM.

Int J Oncol. 2017 Jul;51(1):369-377. doi: 10.3892/ijo.2017.4022. Epub 2017 May 29.

PMID:
28560402
14.

Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2+ γδ T cell cytotoxicity in a perforin-dependent manner.

Fowler DW, Copier J, Dalgleish AG, Bodman-Smith MD.

Cancer Immunol Immunother. 2017 Sep;66(9):1205-1215. doi: 10.1007/s00262-017-2011-1. Epub 2017 May 13.

15.

Effect of the Modification of p24 Peptide Antigen on Dendritic Cell Uptake and T Cell Activation.

Smith PL, Norgate KJ, Hegarty E, Gregeda N, Heelas E, Sommerfelt M, Lange T, Hovden AO, Sorenson B, Dalgleish AG, Bodman-Smith M.

Curr HIV Res. 2017;15(1):3-14. doi: 10.2174/1570162X13666161129115804.

PMID:
27897109
16.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11. No abstract available.

17.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Sep 27;115(7):789-96. doi: 10.1038/bjc.2016.271. Epub 2016 Sep 6. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e16.

18.

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.

Liu WM, Scott KA, Dennis JL, Kaminska E, Levett AJ, Dalgleish AG.

Int J Oncol. 2016 Aug;49(2):793-802. doi: 10.3892/ijo.2016.3567. Epub 2016 Jun 7.

PMID:
27279602
19.

Human Peritoneal Mesothelial Cells Display Phagocytic and Antigen-Presenting Functions to Contribute to Intraperitoneal Immunity.

Shaw TJ, Zhang XY, Huo Z, Robertson D, Lovell PA, Dalgleish AG, Barton DP.

Int J Gynecol Cancer. 2016 Jun;26(5):833-8. doi: 10.1097/IGC.0000000000000697.

PMID:
27120688
20.

Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells.

Scott KA, Dennis JL, Dalgleish AG, Liu WM.

Anticancer Res. 2015 Nov;35(11):5827-37.

PMID:
26504004
21.

Rationale for combining immunotherapy with chemotherapy.

Dalgleish AG.

Immunotherapy. 2015;7(3):309-16. doi: 10.2217/imt.14.111. Review.

PMID:
25804482
22.

Supernatants of tumours treated with chemotherapy can alter tumour growth and development in vivo.

Liu WM, Scott KA, Dalgleish AG.

Anticancer Res. 2015 Mar;35(3):1499-508.

PMID:
25750303
23.

Vaccines versus immunotherapy: overview of approaches in deciding between options.

Dalgleish AG.

Hum Vaccin Immunother. 2014;10(11):3369-74. doi: 10.4161/21645515.2014.980707. Review.

24.

The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model.

Scott KA, Dalgleish AG, Liu WM.

Mol Cancer Ther. 2014 Dec;13(12):2955-67. doi: 10.1158/1535-7163.MCT-14-0402. Epub 2014 Nov 14.

25.

Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing.

Fowler DW, Copier J, Dalgleish AG, Bodman-Smith MD.

Immunology. 2014 Dec;143(4):539-49. doi: 10.1111/imm.12331.

26.
27.

Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.

Cananzi FC, Mudan S, Dunne M, Belonwu N, Dalgleish AG.

Hum Vaccin Immunother. 2013 Nov;9(11):2427-33. Epub 2013 Jul 9.

28.

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.

Lorigan P, Marples M, Harries M, Wagstaff J, Dalgleish AG, Osborne R, Maraveyas A, Nicholson S, Davidson N, Wang Q, Pericleous L, Bapat U, Middleton MR.

Br J Dermatol. 2014 Jan;170(1):87-95. doi: 10.1111/bjd.12503.

PMID:
23855404
29.

Dendritic cell phenotype can be improved by certain chemotherapies and is associated with alterations to p21(waf1/cip1.).

Liu WM, Scott KA, Thompson M, Dalgleish AG.

Cancer Immunol Immunother. 2013 Oct;62(10):1553-61. doi: 10.1007/s00262-013-1456-0. Epub 2013 Jul 4.

PMID:
23824498
30.

Tripartite immune cell co-operation in the Bacillus Calmette Guérin-induced activation of γδ T cells.

Fowler DW, Copier J, Dalgleish AG, Bodman-Smith MD.

Immunol Cell Biol. 2013 Aug;91(7):461-8. doi: 10.1038/icb.2013.30. Epub 2013 Jun 25.

PMID:
23797069
31.

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).

Busse A, Rapion J, Fusi A, Suciu S, Nonnenmacher A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U.

Cancer Immunol Immunother. 2013 Jul;62(7):1223-33. doi: 10.1007/s00262-013-1428-4. Epub 2013 Apr 27.

PMID:
23624802
32.

Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.

Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C.

Immunology. 2013 Jul;139(3):377-85. doi: 10.1111/imm.12087.

33.

Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target?

Liu WM, Dalgleish AG.

Future Oncol. 2012 Jul;8(7):767-9. doi: 10.2217/fon.12.69. No abstract available.

PMID:
22830396
34.

The potential beneficial effects of drugs on the immune response to vaccination.

Liu WM, Dalgleish AG.

Semin Oncol. 2012 Jun;39(3):340-7. doi: 10.1053/j.seminoncol.2012.02.012. Review.

PMID:
22595056
35.

Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis.

Liu WM, Dennis JL, Gravett AM, Chanthirakumar C, Kaminska E, Coulton G, Fowler DW, Bodman-Smith M, Dalgleish AG.

Br J Cancer. 2012 Feb 28;106(5):896-903. doi: 10.1038/bjc.2012.13. Epub 2012 Jan 31.

36.

Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.

Fryer RA, Barlett B, Galustian C, Dalgleish AG.

Anticancer Res. 2011 Nov;31(11):3747-56.

PMID:
22110196
37.
38.

Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy.

Fowler DW, Copier J, Wilson N, Dalgleish AG, Bodman-Smith MD.

Cancer Immunol Immunother. 2012 Apr;61(4):535-47. doi: 10.1007/s00262-011-1121-4. Epub 2011 Oct 15.

39.

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

Ioannou N, Dalgleish AG, Seddon AM, Mackintosh D, Guertler U, Solca F, Modjtahedi H.

Br J Cancer. 2011 Nov 8;105(10):1554-62. doi: 10.1038/bjc.2011.396. Epub 2011 Oct 4.

40.

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.

Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C.

Prostate. 2012 Jun 1;72(8):856-67. doi: 10.1002/pros.21488. Epub 2011 Oct 3.

PMID:
21968939
41.

Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies.

Dalgleish AG.

Vaccine. 2011 Nov 3;29(47):8501-5. doi: 10.1016/j.vaccine.2011.09.012. Epub 2011 Sep 18. Review.

PMID:
21933695
42.

Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses.

Liu WM, Fowler DW, Gravett AM, Smith P, Dalgleish AG.

Br J Cancer. 2011 Aug 23;105(5):687-93. doi: 10.1038/bjc.2011.306. Epub 2011 Aug 9.

43.

The gene expression profile of unstimulated dendritic cells can be used as a predictor of function.

Liu WM, Dennis JL, Fowler DW, Dalgleish AG.

Int J Cancer. 2012 Feb 15;130(4):979-90. doi: 10.1002/ijc.26101. Epub 2011 Jun 21.

44.

Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids.

Liu WM, Fowler DW, Dalgleish AG.

Curr Clin Pharmacol. 2010 Nov;5(4):281-7. Review.

PMID:
20925645
45.

The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.

Liu WM, Gravett AM, Dalgleish AG.

Int J Cancer. 2011 Mar 15;128(6):1471-80. doi: 10.1002/ijc.25707. Epub 2010 Nov 28.

46.

In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents.

Gravett AM, Liu WM, Krishna S, Chan WC, Haynes RK, Wilson NL, Dalgleish AG.

Cancer Chemother Pharmacol. 2011 Mar;67(3):569-77. doi: 10.1007/s00280-010-1355-4. Epub 2010 May 19.

PMID:
20490800
47.
48.

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

Bergmann L, Berns B, Dalgleish AG, von Euler M, Hecht TT, Lappin GL, Reed N, Palmeri S, Smyth J, Embacher-Aichorn S, Zwierzina H; Biotherapy Development Association.

Ann Oncol. 2010 Aug;21(8):1573-8. doi: 10.1093/annonc/mdq018. Epub 2010 Feb 4. Review.

49.

How immunotherapy can enhance the response to other modalities and improve outcome and quality of life.

Liu WM, Meyer B, Dalgleish AG.

J BUON. 2009 Sep;14 Suppl 1:S103-9. Review.

PMID:
19785052
50.

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.

Liu WM, Fowler DW, Smith P, Dalgleish AG.

Br J Cancer. 2010 Jan 5;102(1):115-23. doi: 10.1038/sj.bjc.6605465. Epub 2009 Dec 8.

Supplemental Content

Loading ...
Support Center